PCL Patient Resources

In unanimous fashion, the FDA AMDAC voted 21 to 0 that nirsevimab has a favorable benefit risk profile for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

Hidden triggers and asthma mimickers can complicate this common childhood condition.

Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.

New data quantify the exposure to wildfire particulate matter among schoolchildren in California, finding that interventions in a small number of schools may reduce the overall burden of wildfire PM2.5 exposure.

In a recent study, vaccination administered during pregnancy was effective against severe lower respiratory tract illness associated with respiratory syncytial virus (RSV) in infants.